ERA Congress 2025
Rajiv Agarwal discussed a study showing that a finerenone-empagliflozin combo has superior efficacy in CKD and T2D.
Phase 3 VISIONARY trial data showed sibeprenlimab helps achieve significant proteinuria reduction in IgAN.
Treatment with a finerenone-empagliflozin combo leads to greater decreases in albuminuria in CKD and type 2 diabetes.
Pegcetacoplan reduced proteinuria and stabilized eGFR in adolescent patients with C3G or primary IC-MPGN.
An analysis confirmed the efficacy and safety of pegcetacoplan for patients with C3G/IC-MPGN and nephrotic range proteinuria.
Treatment effects of nefecon were consistent independent of baseline eGFR among patients with IgAN.
A study highlights the role of NPT2b in tubulointerstitial fibrosis and CKD progression.
Researchers identified three immune phenotypes of checkpoint inhibitor-induced acute interstitial nephritis.
A study assessed whether the cardiovascular and renal effects of canagliflozin are dose dependent.
Research identified the optimal biomarker combination to predict interstitial fibrosis surface in IgA nephropathy.
Survival benefits of deceased-donor kidney transplantation decrease when older patients receive lower quality organs.
Long-term data demonstrated that zigakibart reduced proteinuria and stabilized kidney function of patients with IgAN.
Winners of the 2025 ERA Awards and ERA Awards for Young Investigators were recognized at the 62nd ERA Congress.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.